



10745 Westside Way, Suite 200

Alpharetta, GA 30009

Tel: +1 (844) 884 5367

Email: info@vtivision.com

www.vtvision.com

www.vtvisioninvestors.com (for investors)

ASX Announcement

Visioneering Technologies, Inc. Restatement of 2016 Audited Financial Statements and 30 June 2017 Half-Year Reviewed Financial Statements

Atlanta, Georgia, USA 4 February 2018: Visioneering Technologies, Inc (ASX: VTI), a US-based medical device company ('Visioneering' or 'The Company') has announced today that it will make certain non-cash changes to its audited financial statements for the year ended 31 December 2016 ('FY 2016') and reviewed half-year financial statements for the period ended 30 June 2017 ('HY 2017').

Specifically, the Company's Senior, Series A-1 and Pre-IPO Notes that were converted to shares of common stock in connection with the Company's Initial Public Offering ('IPO') in March 2017 should have included derivative accounting. The restatement will result in expenses in FY 2016 increasing by US\$3.3 million and expenses in HY 2017 decreasing by \$0.4 million.

There will be no impact on the Company's net cash flow for either FY2016 or HY2017 or future cash flows.

Visioneering is working with its auditors to finalise the restated financial statements. Comparative balances will be included in the financial statements for the 2017 year-end financial statements and 2018 half-year financial statements to reflect these adjustments.

The following table shows the summary effect of the unaudited adjustments.

(Amounts in millions of US dollars except share and per share amounts)	12 months	6 months
	ended 31 December 2016	ended 30 June 2017
Interest expense reported	\$1.3	\$4.0
(Increase)/decrease in interest expense and derivatives loss	3.3	(0.4)
Interest expense and derivatives expense, restated	\$4.6	\$3.6
Net loss, originally reported	(\$5.0)	(\$10.3)
(Increase)/decrease in interest expense and derivatives loss	(3.3)	0.4
Net loss, restated	(\$8.3)	(\$9.9)

For more information, please contact:

Company	Investor and media relations
Stephen Snowdy CEO, Visioneering Technologies, Inc. Email: ssnowdy@vtivision.com	Kyahn Williamson WE Buchan Tel: +61 (3) 9866 4722 Email: kwilliamson@buchanwe.com.au

Foreign ownership restrictions:

VTI's CHESD Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.